Age-Specific Prevalence of Epstein-Barr Virus Infection Among Individuals Aged 6-19 Years in the United States and Factors Affecting Its Acquisition
Age-Specific Prevalence of Epstein-Barr Virus Infection Among Individuals Aged 6-19 Years in the United States and Factors Affecting Its Acquisition
复制标题
DOI：
10.1093/infdis/jit321
复制
发表时间：
2013-10-15
影响因子：
6.4
通讯作者：
Thomas, William
中科院分区：
文献类型：
--
作者：
Balfour, Henry H., Jr.;Sifakis, Frangiscos;Thomas, William
背景。 EB 病毒 (EBV) 感染的特定年龄患病率数据与确定何时接种预防性疫苗相关。人口统计群体的比较可以确定与其获得相关的因素。方法。国家健康和营养检查调查 (NHANES) 对美国人口的代表性样本进行了调查。通过酶免疫分析 (EIA) 对 6-19 岁 NHANES 参与者的血清样本进行了 EBV 抗体检测。还通过间接免疫荧光（IFA）测试了随机部分。患病率估计和风险因素比较使用人口统计数据和逻辑回归模型中的抽样权重。结果。对 2003 年至 2010 年间从参加 NHANES 的 9338 名个体采集的血清样本进行了测试。 EIA 和 IFA 结果之间的一致性为 96.7%。年龄调整后的 EBV 抗体总体患病率从 2003-2004 年的 72% 下降到 2009-2010 年的 65% (P = .027)。 2009-2010年按年龄组的患病率如下：6-8岁，50%； 9-11岁，55%； 12-14岁，59%； 15-17岁，69%； 18-19岁，89%。在每个种族/民族群体中，年龄较小、健康保险覆盖范围、家庭收入较高和教育水平与 EBV 抗体患病率较低显着相关。结论。从2003-2004年到2009-2010年，美国6-19岁人群的EBV抗体患病率有所下降，主要是因为非西班牙裔白人参与者的下降。随着时间的推移，抗体流行率不断下降，而且 12-19 岁参与者中观察到的流行率持续较高，支持 12 岁之前广泛使用 EBV 疫苗。
Background. Data on the age-specific prevalence of Epstein-Barr virus (EBV) infection are relevant for determining when to administer a prophylactic vaccine. Comparison of demographic groups could identify factors associated with its acquisition.Methods. The National Health and Nutrition Examination Surveys (NHANES) examine a representative sample of the US population. Serum specimens from NHANES participants 6-19 years old were tested for EBV antibody by enzyme immunoassay (EIA). A random portion was also tested by indirect immunofluorescence (IFA). Prevalence estimates and risk-factor comparisons used demographic data and sampling weights in logistic regression models.Results. Serum specimens collected between 2003 and 2010 from 9338 individuals participating in NHANES were tested. The concordance between EIA and IFA findings was 96.7%. The overall age-adjusted EBV antibody prevalence declined from 72% in 2003-2004 to 65% in 2009-2010 (P = .027). The prevalence in 2009-2010 by age group was as follows: 6-8 years, 50%; 9-11 years, 55%; 12-14 years, 59%; 15-17 years, 69%; and 18-19 years, 89%. Within each race/ethnicity group, younger age, health insurance coverage, higher household income, and education level were significantly associated with a lower prevalence of EBV antibody.Conclusions. The EBV antibody prevalence declined in US individuals aged 6-19 years from 2003-2004 to 2009-2010, mainly because of the decrease among non-Hispanic white participants. The declining antibody prevalence over time and the consistently high observed prevalence among participants aged 12-19 years support broad use of EBV vaccine before 12 years of age.